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Background: The existing shortage of animal models that properly 
mimic the progression of early-stage human lung cancer from a soli-
tary confined tumor to an invasive metastatic disease hinders accu-
rate characterization of key interactions between lung cancer cells 
and their stroma. We herein describe a novel orthotopic animal model 
that addresses these concerns and consequently serves as an attrac-
tive platform to study tumor–stromal cell interactions under condi-
tions that reflect early-stage lung cancer.
Methods: Unlike previous methodologies, we directly injected small 
numbers of human or murine lung cancer cells into murine’s left lung 
and longitudinally monitored disease progression. Next, we used green 
fluorescent protein-tagged tumor cells and immuno-fluorescent 
staining to determine the tumor’s microanatomic distribution and to 
look for tumor-infiltrating immune cells and stromal cells. Finally, we 
compared chemokine gene expression patterns in the tumor and lung 
microenvironment.
Results: We successfully generated a solitary pulmonary nodule sur-
rounded by normal lung parenchyma that grew locally and spread 
distally over time. Notably, we found that both fibroblasts and leuko-
cytes are recruited to the tumor’s margins and that distinct myeloid 
cell attracting and CCR2-binding chemokines are specifically 
induced in the tumor microenvironment.
Conclusion: Our orthotopic lung cancer model closely mimics the 
pathologic sequence of events that characterizes early-stage human 
lung cancer propagation. It further introduces new means to monitor 
tumor–stromal cell interactions and offers unique opportunities to 
test therapeutic targets under conditions that reflect early-stage lung 
cancer. We argue that for such purposes our model is superior to lung 
cancer models that are based either on genetic induction of epithelial 
transformation or on ectopic transplantation of malignant cells.
Key Words: Non–small-cell lung cancer, Lung, Orthotopic animal 
model, Tumor microenvironment.
(J Thorac Oncol. 2015;10: 46–58)
Lung cancer is the second most common malignancy and the leading cause of cancer-related death in the United 
States and throughout the world.1 Out of all lung cancer cases, 
patients who are diagnosed with early-stage disease (stages 
IA–IIB) have the best prognosis.2 These patients are con-
sidered to have a solitary pulmonary tumor that has not yet 
metastasized and, therefore, are referred to surgery which is 
considered to be the best therapeutic approach.3 Nonetheless, 
about 50% of these patients eventually succumb to the disease 
due to either local recurrence of the tumor or to its metastatic 
spread.2,3 To be able to develop innovative therapeutics for 
these patients, novel insights into the processes that govern the 
growth and metastasis of early-stage lung cancer are urgently 
needed.4–6 In particular, it is important to study the interac-
tions of lung cancer tumor cells with their native lung micro-
environment and to try and understand how these processes 
regulate tumor growth and spread.7–9 Unfortunately, the study 
of these critical issues is hampered, in part, by the lack of an 
appropriate animal model that accurately mimics the patho-
logic sequence of events that characterizes early-stage human 
lung cancer: a single pulmonary nodule that is surrounded by 
normal lung parenchyma and that, over time, locally grows 
and forms metastasis.10–12
More specifically, existing lung cancer models fall into 
two main categories, and both do not allow accurate mimicry 
of lung caner disease progression. One set of models is based 
on the induction of epithelial transformation, either by the 
administration of a chemical carcinogens or by genetically 
regulating the expression of a specific oncogenes or tumor 
suppressor genes in the lung.13 For example, exposure of mice 
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to the tobacco-specific carcinogen 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone induces the activation of multiple 
pro-proliferative signaling pathways such as ERK1/2, PKC, 
PI3K/Akt, and MAPK, that eventually lead to lung tumori-
genesis.14 Alternatively, lung epithelial transformation may be 
stimulated either by enhancing the expression of a tumor driv-
ing mutation such as K-RAS or by silencing the expression 
of a tumor suppressor genes such as P53 in the lung paren-
chyma.15,16 An important advantage of the genetic approach 
is that it facilitates the characterization of single tumor-pro-
moting pathways under regulated conditions and also per-
mits the testing of pathway-specific inhibitors as potential 
new drugs.17 Nonetheless, one of the most frequent criticisms 
about epithelial transformation-based lung cancer models is 
that they inherently modify the entire lung microenvironment 
and also induce the formation of multiple bilateral tumors that 
only rarely recapitulate the metastatic phenotype seen within 
human tumors.18 As such, these models limit the potential to 
assess how a solitary lung tumor interacts with the native lung 
microenvironment and how, for example, such a tumor metas-
tasizes to the contralateral lung. Further limitations of such 
models are related to the long time elapsed till tumor forma-
tion, the relative complexity of the modeling system, and the 
high cost of some of these models.19,20
The second set of approaches used to model lung can-
cer is based on ectopic delivery of either cancerous cell lines 
or of patient-derived tumor xenografts. And yet, these models 
display other kinds of limitations. For example, cancerous cell 
line-based models require the injection of very large number of 
cells, which, as a result, can overwhelm and escape the normal 
immune response against primary tumors.21 This large volume 
of cells may also induce a rapid and extensive inflammatory 
response which masks the physiologic events that accompany 
initial phase tumors.21 Another important issue to consider 
with regard to the ectopic approach is to do with the method 
and site of tumor induction. For example, tail-vein injection of 
the cancerous cells is associated with spread of the cells to the 
entire organism and with the generation of multiple tumors 
(Supplementary Figure 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A712). Therefore, although this 
approach can be used to probe tumor metastasis to the lung, 
it cannot be used to study tumor formation in the lung.10,11,22 
Also problematic is the subcutaneous administration of the 
cancerous cells or the subcutaneous implantation of human-
derived tumor xenografts, which by definition introduces the 
cells to a microenvironment that is totally different from the 
tumors original microenvironment. Collectively, although 
the above-described experimental approaches have provided 
many important molecular insights into the process of lung 
cancer initiation and into the process of non-lung cancer 
malignant tumor cell metastasis to the lung, they fall short in 
providing an appropriate system to probe how a single pulmo-
nary nodule propagates in the native lung microenvironment 
and how it spreads to secondary organs.10–12
In light of these considerations, we reasoned that ortho-
topic transplantation of lung cancer cells might overcome 
some of these limitations. Although several previous attempts 
with this approach have been made, they have all been only 
partially successful due to technical limitations that prevented 
the generation of a single pulmonary nodule that was anatomi-
cally confined to the lung and that, over time, locally grew and 
spread in a manner that resembles the growth and metastasis of 
human non–small-cell lung cancer (NSCLC).23,24 In this arti-
cle, we address these concerns and describe a novel and refined 
orthotopic animal model that can, consequently, serve as an 
attractive platform to study the crosstalk between tumor cells 
and the lung microenvironment. Distinct from previous meth-
odologies, our approach involves stereotactic-guided injection 
of a minute number of cells in the microliter range of volumes, 
directly into the left lobe of the murine lung. Mimicking real 
disease progression, this novel orthotopic approach allowed 
us to successfully generate a solitary microscopic pulmonary 
nodule that is surrounded by normal lung parenchyma and to 
systematically follow its growth and spread for a period of 1 
to 6 weeks. This methodology further enabled us for the first 
time to introduce an animal model in which a solitary lung 
tumor metastasizes from the lung to secondary organs such as 
the contralateral lung and liver. Finally, in search of key path-
ways that might contribute to tumor progression, the model 
also allowed us to identify certain chemotactic molecules and 
distinct populations of fibroblasts and myeloid cells that may 
serve as potential therapeutic targets for lung cancer therapy.
MATERIALS AND METHODS
Cell Lines
The human H460 (large cell carcinoma) and A549 
(adenocarcinoma) cell lines as well as the murine 3LL (also 
known as Lewis lung carcinoma) cell line were all purchased 
from American Type Culture Collection (Manassas, VA) and 
were maintained in RPMI (Gibco Laboratories, Grand Island, 
NY) containing 10% fetal calf serum, 1 mM L-glutamine, 
100 U/ml penicillin, and 0.01 mg/ml streptomycin (Biological 
Industries, Kibbutz Beth Haemek, Israel). All cell lines were 
tested for mycoplasma contamination and were found to be 
negative.
In Vivo Experimental Design
For experiments in the syngeneic system, we injected 
3LL cells to C57BL/6 immune-competent mice. For experi-
ments in the humanized system, we injected H460 and A549 
cells (human lung cancer cells) to NSG immune-deficient 
mice.
•  To calibrate the model, 15 C57BL/6 were injected with 
250, 500, or 1000 3LL cells (five mice per group). To 
assess for tumor formation, mice were killed after 3 weeks.
•  To assess the ability of micro-positron emission tomog-
raphy/computed tomography (PET/CT) to detect the 
tumors, five C57BL/6 were injected with 500 3LL cells 
and imaging was performed 3 weeks after tumor cell 
implantation.
•  To assess the tumor histology, 1 week after tumor cell 
injection, five C57BL/6 were injected with 500 3LL cells 
and killed at the indicated time point.
•  For the immuno-fluorescent staining, 10 C57BL/6 were 
injected with 500 GFP-tagged 3LL cells. The mice were 
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killed (five mice per group) 1 and 3 weeks after tumor 
cell implantation.
•  For the analysis of tumor-infiltrating and lung leukocytes, 
five C57BL/6 were injected with 500 3LL cells. Mice 
were killed 3 weeks after tumor cell implantation. Next, 
the tumor-infiltrating and lung resident leukocytes were 
extracted as described below. This experiment was repeated 
three times; thus, the total number of injected mice was 15.
•  For the gene-chip analysis and quantitative polymerase 
chain reaction (qPCR), five C57BL/6 were injected with 
500 3LL cells and the mice were killed 3 weeks after 
tumor cell implantation.
•  To assess for the production of CCL2 and CCL7 in the 
tumors, five C57BL/6 were injected with 500 GFP-
tagged 3LL cells. The mice were killed 3 weeks after 
tumor cell implantation. Three control non-tumor-bear-
ing mice were also killed.
•  For the immunohistochemistry staining, 5 C57BL/6 were 
injected with 500 GFP-tagged 3LL cells. The mice were 
killed 3 weeks after tumor cell implantation.
•  To assess for tumor formation by H460 cells, 12 NSG 
mice were injected with 7.5 × 103 or 104 H460 cells (six 
mice per group) and mice were killed after 6 weeks.
•  To assess for tumor formation by A549 cells, five NSG 
mice were injected with 5 × 103 A549 cells and mice were 
killed after 6 weeks.
Detailed Description of the Surgical Procedure
Cultured H460, A549 (5 × 103 or 104 per 1 μl), and 3LL 
(250, 500, or 1000 per 1 μl) cells were harvested and sus-
pended in RPMI-1640 (BD Bioscience, NJ). Before injec-
tion, the cells were mixed with matrigel (BD Bioscience) at 
1:1 ratio and kept on ice until injection. For injection, the 
cell mixture was gently mixed and transferred into a 10-μl 
syringe (Hamilton, NV, USA) fitted with a 31-gauge needle. 
The syringe was loaded on the stereotactic injection system, 
and 2 μl of cell mixture was injected to each mouse.
Mice were anesthetized using ketamine/xylasine and 
the fur covering the left thorax was shaved. The mice were 
then positioned in the lateral decubitus position with the left 
chest facing up and a small (0.5–1 cm) incision was made over 
the skin just below the scapula. Next, the chest wall muscles 
were gently spread until the intercostal space and pleura were 
clearly visible. Then, the ribs were counted from the lower 
border of the rib cage upward, and the site of tumor injec-
tion between the fourth and fifth ribs at the posterior axillary 
line was determined. At this stage, the syringe was gently 
advanced until its tip finely touched the intercostal space. The 
syringe was then advanced 3.5 mm into the lung parenchyma 
and the tumor cell mixture was injected. After injection of the 
cells, the syringe was withdrawn from the tissue and the cov-
ering muscles and skin were closed. Subsequently, mice were 
given an analgesic medication and were allowed to recover in 
a preheated incubator for 20 to 30 minutes.
Lung harvesting was performed as follows: mice were 
first euthanized by overdose injection of ketamine/xylasine. 
Next, the chest cavity was exposed and the lungs perfused with 
4% buffered paraformaldehyde through the trachea. For frozen 
section preparation, the lungs were perfused with 2% buffered 
paraformaldehyde through the trachea and frozen in OCT.
The animal care and use committee at Hadassah University 
Hospital approved the experimental protocol used in this article.
Micro-PET/CT Imaging
One hour before micro-PET/CT scanning, tumor-
bearing mice were tail-vein injected with 200 uCi 
18F-Fluorodeoxyglucose. All acquisitions were carried 
out using the Inveon multimodality PET/CT small animal-
dedicated scanner (Siemens Medical Solutions, USA Inc.). 
Emission sinograms were normalized and corrected for 
attenuation, randoms, dead time, and decay. Image recon-
struction was performed using Fourier rebinning and two-
dimensional ordered-subsets expectation maximization, with 
a voxel size of 0.776 × 0.776 × 0.796 mm3. Image analysis was 
performed using Inveon Research Workplace 3.1 (Siemens 
Medical Solutions, USA Inc.).
Histology, Hematoxylin and Eosin, 
Fluorescent Immuno-Staining, and 
Immunohistochemistry Staining
Tissue samples of control lungs and tumor-bearing lungs 
were routinely fixed with formalin and embedded in paraffin. 
Tissues were then serially sectioned in 4 to 7 μM distances 
and transferred to slides for hematoxylin and eosin staining.
For immuno-fluorescent staining, the following anti-
bodies were used: GFP was amplified by chicken polyclonal 
antibodies to GFP (ab13970; Abcam, Cambridge, England, 
United Kingdom) followed by Alexa 488 donkey anti-chicken 
secondary antibodies (Jackson, 703-545-155). Rabbit pAb to 
S100A4 (ab27957; Abcam) followed by Alexa 647 donkey 
anti-rabbit secondary antibodies (Jackson, 711-605-152; JAX 
Mice, Clinical & Research Services, Bar Harbor, ME) and 
PE-conjugated anti-mCD45 (clone 30-F11, Biolegend, San 
Diego, CA). For immunohistochemistry, slides were incu-
bated with anti-CD45 (Abcam, ab10558) or anti-aSMA (DAKO 
M0851). 3-Amino-9-ethylcarbazole was used for color develop-
ment and sections were counterstained with hematoxylin.
Isolation of Tumor-Infiltrating 
Leukocytes (CD45+)
Three weeks after injection of 3LL cells to C57BL/6 
mice, the mice were killed and the lungs were perfused by 
injection of saline to the right heart ventricle. Next, the lungs 
were harvested and the left lobe tumors were carefully dis-
sected from the left lung parenchyma. The right lung lobes 
were used as a non-tumor-bearing control sample. In each 
experiment, the tumor and lung samples from five mice were 
pooled together to yield a large number of leukocytes. Both 
lung and tumor specimens were roughly minced and put in 
RPMI containing collagenase IV and DNase (200 μg/ml 
and 5 μg/ml, respectively, both from Worthington, Lakewood, 
NJ) for 40 minutes at 37°C. Afterward, samples were meshed 
through a 70-μm disposable mesh (Falcon, BD Bioscience) 
and washed twice with phosphate buffered saline (wash buf-
fer) containing 4% FBS (Biological Industries). Samples were 
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reconstituted in 100-μl wash buffer, blocked with 1% mouse 
serum, and separated using anti-mouse CD45 magnetic beads 
(Miltenyi, Germany) as described by the manufacturer.
Flow Cytometry
Isolated tumor-infiltrating cells and lung resident cells 
were stained with eFluor450-labeled anti-CD45.2, APC-labeled 
anti-CD11b, and FITC-labeled anti-Gr-1. All antibodies were 
purchased from eBioscience (San Diego, CA). Next, the cells 
were washed twice with PBS and then stained for dead cells with 
the Dead Cell Marker (Invitrogen, Grand Island, NY). Cells were 
acquired on a LSR-II flow cytometer (BD Bioscience) and there-
after analyzed using FlowJo software (Tree Star, Ashland, OR).
Gene-Chip Protocol
Total RNA was extracted from normal lung tissue, 3LL 
tumor tissue, and from 3LL cells growing in culture. The RNA 
was subjected to gene expression profiling using GeneChip 
Mouse Gene 1.0 ST Array (Affymetrix, Santa Clara, CA) 
according to the manufacturer’s protocol.
Quantitative PCR Analysis
Quantitative PCR analysis of the expression of the che-
mokines CXCL-2, 3, 12, 16 and CCL-2, 3, 5, 7, 17, 22 was 
performed using TaqMan technology (Applied Biosystems and 
Invitrogen). TaqMan fast universal PCR master mix and specific 
primers were purchased from the company and the experiment 
was performed according to the manufacturer’s instructions. For 
each tissue sample, the experiment was performed in triplicate.
Enzyme-Linked Immunosorbent Assay
3LL-derived lung tumors and control normal lung tissue 
samples were homogenized in Greenberger Lysis Buffer con-
taining 300 mM NaCl,15 mM Tris, 2 mM MgCl
2
, 2 mM Triton 
(X-100), and protease inhibitors (Complete Mini Roche diag-
nostic GmbH, Mannheim, Germany, Ref 11836153001) one 
tablet per 10 ml. One milligram of tissue was homogenized 
in 20 μl lysis buffer. After homogenization, the suspension 
was centrifuged and CCL2 and CCL7 were determined in the 
supernatant by enzyme-linked immunosorbent assay (ELISA) 
according to the manufacture’s instructions. For CCL2, the 
Quantikine ELISA kit (R&D systems Inc., Minneapolis, MN) 
was used. For CCL7, the instant ELISA kit by eBioscience/
bender medsystems (Vienna, Austria) was used. Protein con-
tent in each tissue sample was determined by Bradford assay 
and the chemokine content in each sample was then calculated 
relative to the protein content in the sample to yield chemo-
kines expressed in picograms per milligram of protein scale.
RESULTS
Intra-Parenchymal Injections of Minute 
Numbers of Murine Lung Cancer Cells 
Successfully Generate a Single Pulmonary 
Nodule that is Detectable by PET/CT
In the first set of experiments, we aimed to generate 
a single pulmonary nodule by injecting very small numbers 
of murine lung cancer cells (3LL) directly into the left lung 
parenchyma. We targeted the murine left lung because in this 
species, the left lung consists of only one lobe, hence assur-
ing the accurate delivery of the malignant cells to a distinct 
anatomic compartment (Fig. 1A). In addition, in an attempt 
to reduce potential tissue damage and to prevent spillage of 
cells from the lung to the thoracic cavity, we used a very fine 
needle and suspended the cells with matrigel to a total vol-
ume of injection of 2 μl, a volume that represents only about 
0.5% of the left lung volume. To calibrate the rate of tumor 
formation, we injected dosages of 250, 500, or 1000 murine 
3LL lung carcinoma into the left lung of C57BL/6 mice and 
3 weeks later killed the mice. Pulmonary nodules formed in 
60% (3 of 5), 80% (4 of 5), and 100% (5 of 5) of mice injected 
with 250, 500, and 1000 cells, respectively. Importantly, as 
shown in Figure 1B, the mice developed a single pulmonary 
nodule and no chest wall tumor or mediastinal masses were 
observed. When keeping tumor-bearing mice alive for 4 
weeks, the 3LL tumors tended to outgrow from the lung and 
to invade the tumor adjacent chest wall (data not shown). At 
this time point, the mice showed reduction in body weight 
and reduced mobility and thus in further experiments, we did 
not keep tumor-bearing mice alive for more than 3 weeks. 
Next, we tested whether micro-PET/CT imaging could detect 
the pulmonary nodule in live anesthetized mice. As expected, 
and as shown in Figure 1C–E, both the CT and PET modali-
ties clearly demonstrated the pulmonary nodule in the left 
lung, thereby supporting the notion that the tumor is localized 
to a single locus.
Orthotopically Implanted 3LL Cells Display a 
Locally Aggressive Growth Pattern Mimicking 
the Growth of Invasive Stage I Human NSCLC
In the next phase of the article, we set to determine 
the tumor’s microscopic characteristics and to confirm that 
indeed a single pulmonary nodule is formed after tumor 
implantation. To this end, histologic serial sections were pre-
pared from the lungs of mice injected with 500 3LL cells 
and killed at 1 and 3 weeks after tumor cell implantation. As 
can be seen in Figure 2B, microscopic examination of slides 
from the 1-week time point indicated the formation of a soli-
tary small tumor that was surrounded by normally appearing 
lung parenchyma. Similarly, examination of slides from the 
3-week time point also indicated the formation of a singular 
tumor. However, as expected at this time point, the tumor was 
much larger and exerted mass effects on the tumor surround-
ing lung parenchyma (Fig. 2C). Focusing on areas of inter-
face between the 3-week-old tumor and the lung parenchyma, 
we found that the 3LL tumor cells invaded neighboring alve-
olai and also engulfed pulmonary vascular structures (Fig. 
2D). In addition, we noticed the remarkable accumulation of 
leukocyte infiltrates at areas of interface between the tumor 
and tumor adjacent lung parenchyma as well as around blood 
vessels in the tumor vicinity (Fig. 2D and Supplementary 
Figure 2A and 2B, Supplemental Digital Content 2, http://
links.lww.com/JTO/A713).
To further validate the surgical technique and confirm 
that indeed only a solitary tumor focus was formed, we next 
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followed the growth of GFP-tagged 3LL cells in vivo. As 
anticipated, microscopic examination of the left lung at 1 and 
3 weeks after tumor cell injection confirmed the generation of 
a singular tumor in the left lung field (Fig. 2E, F). Remarkably, 
no GFP-positive cells were detected at sites distant from the 
primary tumor focus (Fig. 2E, F) or in remote lobes (data 
not shown), thus indicating that no individual cancer cells 
were shed from the original solitary tumor. Collectively, 
FIGURE 1. A, Schematic illustration of the anatomy of the murine lung indicating the existence of a single left lung lobe. The 
black line represents the pleura and the black arrow and red circle indicate trans-pleural injection of tumor cells into the left 
lung parenchyma. B, Representative image of the chest of a C57BL/6 mouse that was killed 3 weeks after injection of 500 3LL 
cells directly into the left lung. The black arrow points to a macroscopic single pulmonary nodule in the left lung. LL, left lung; 
PCL, postcaval lobe of right lung. C–E, Representative micro-PET/CT imaging of a C57BL/6 mouse 3 weeks after injection of 3LL 
cells directly into the left lung. A, CT sections, (B) PET sections, and (C) PET/CT superposition. Upper panels show axial sections 
and lower panels show coronal reconstructions. Arrowheads mark the tumor and arrows point to the heart. PET/CT, positron 
emission tomography/computed tomography.
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FIGURE 2. A–D, Representative 
histologic sections from the lungs of 
C57BL/6 mice that were killed 1 and 
3 weeks after injection of 3LL (Lewis 
lung carcinoma cells) into the left 
lung. A, Control noninjected lung 
(magnification, ×10); (B) tumor 1 
week after injection (magnification, 
×10); (C) tumor 3 weeks after injec-
tion (magnification ×4); (D) tumor 3 
weeks after injection. Red arrowheads 
indicate tumor cells that invade the 
alveolar space at the tumor periph-
ery and black arrowheads indicate 
immune cells surrounding a large 
vessel (arrow) in tumor periphery; 
note that tumor cells begin to engulf 
the vessel, white arrowheads point 
to small microvessels inside the 
tumor (magnification ×20). E and F, 
Representative immuno-fluorescent 
staining of histologic frozen sections 
from the lungs of C57BL/6 mice 
killed 1 and 3 weeks after injection of 
500 GFP-expressing 3LL cells into the 
left lung. Green: anti-GFP staining, 
blue: Hoechst nuclear staining.  
Bar = 100 μm. E, Tumor cells were 
visualized by anti-GFP staining of the 
left lung 1 week after injection and 
(F) tumor cells were visualized by 
anti-GFP staining of the left lung 3 
weeks after injection.
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these observations validate the solitary nature of our ortho-
topic model and further suggest that the 3LL tumors display 
a locally invasive growth pattern that mimics the behavior of 
locally invasive stage I human NSCLC.
3LL Cells Recruit Fibroblasts and Distinct 
Populations of Leukocytes to Their 
Vicinity during Tumor Progression
To further elucidate the composition of stromal lung cells 
within and nearby the growing tumor, we next stained either 
the tumor or lung areas remote from the tumor for markers 
of two main cell populations known to comprise the tumor 
stroma: (1) lung fibroblasts (identified by the lung fibroblast 
marker, S100A425 and by aSMA)26 and (2) leukocytes (identi-
fied by CD45). Notably, 1 week after tumor implantation, no 
S100A4-positive cells could be found inside or nearby GFP-
labeled tumor cells; 2 weeks later, as the tumor grew, a thin 
layer of S100A4-positive cells appeared at the margin of the 
growing tumor, with a negligible number of S100A4-positive 
cells detected at lung sections distant to the tumor (Fig. 3A–C). 
Given that some malignant cells including lung cancer cells can 
also express the S100A4 marker and to exclude the possibility 
that all S100A4-positive cells were tumor cells, we examined 
our staining at a higher degree of magnification27,28 As shown 
in Figure 3D, multiple S100A4-positive cells at the tumor edge 
were GFP negative suggesting that these were cancer-associated 
fibroblast. In addition, some of the S100A4 cells were also posi-
tive for GFP indicating that these are S100A4-expressing tumor 
cells. To further solidify the observation that fibroblasts were 
recruited to the tumor edge, we next stained tumor sections for 
an additional cancer-associated fibroblast marker: aSMA, as 
expected we found that aSMA-positive cells were indeed abun-
dant in the tumor margin. Notably, some aSMA-positive cells 
were also detected in the tumor bulk indicating recruitment of 
these cells not only to the tumor edge but also to the tumor 
parenchyma (Supplementary Figure 3A, Supplemental Digital 
Content 3, http://links.lww.com/JTO/A714).26
In addition to fibroblasts, we also found that the density 
of leukocytes (CD45+ cells) in the margin of the 3-week-grow-
ing tumor was significantly higher than in remote lung areas 
distant to the tumor (Fig. 4A, B). Notably, the density of these 
CD45+ cells in areas distant to the tumor was comparable to 
that in normal lungs (data not shown). To further probe the sub-
populations of tumor-infiltrating and lung resident leukocytes, 
we extracted CD45+ cells from the tumor and lung, respec-
tively, and characterized them by flow cytometry. As shown in 
Figure 4C (left panels), we found that the portion of CD45+ 
cells that display high forward and side scatter was increased in 
the tumors relative to normal lung tissue and that upon gating 
on these cells and staining for CD11b and GR1, we could spe-
cifically detect the accumulation of CD45+ Gr-1med CD11bhigh 
leukocytes in the tumors relative to normal lung (Fig. 4C; right 
panels). Interestingly, data from the literature suggest that such 
CD45+ Gr-1med CD11bhigh cells represent myeloid-derived sup-
pressor cells, which can exert various immune suppressive 
properties in the tumor microenvironment.29 More broadly, 
the accumulation of both fibroblasts and leukocytes in the 
tumor–stroma interface strongly supports the notion that our 
orthotopic tumor implantation model affords a powerful tool 
to dissect temporal tumor and stromal changes at a single cell 
level in distinct compartments of a growing tumor.
3LL Tumors Express a Distinct Milieu 
of Chemokines that may Implicate 
Tumor–Stroma Communications
In the next part of the article, we set out to identify 
tumor-expressed functional molecules that potentially par-
ticipate in the interactions between tumor cells and the lung 
microenvironment. To this end, we first performed a whole 
genome gene-chip analysis comparing the genomic expres-
sion patterns of 3LL tumors to those of normal lung tissue 
and of 3LL cells growing in culture. Focusing on the intensity 
of chemokine mRNA expression in the gene chip, we defined 
four groups of chemokines: (1) chemokines whose mRNA 
expression is nearly absent both in cultured 3LL cells and 
in the lungs (CXCL2 and CXCL3); (2) chemokines whose 
mRNA is expressed by cultured 3LL cells but is absent in 
the lungs (CCL2 and CCL7); (3) chemokines whose mRNA 
is absent in cultured 3LL cells but is highly expressed in the 
lungs (CXCL12, CXCL16, and CCL5, also defined as lung 
homeostatic chemokines); and (4) chemokines whose mRNA 
levels are low in cultured 3LL cells but show intermediate 
expression in the lungs (CCL3, CCL17, and CCL22). We next 
assessed the expression of these chemokines by qPCR. As 
shown in Figure 5A–D, the mRNA of the myeloid cell attract-
ing chemokines (CXCL2 and CXCL3) and the CCR2-binding 
chemokines (CCL2 and CCL7) was specifically induced 
in the tumor microenvironment, whereas the mRNA of the 
lung homeostatic chemokines (those whose mRNA is highly 
expressed in the normal lung: CXCL12, CXCL16, and CCL5) 
were suppressed in the tumors.30–33
To confirm that indeed the chemokines whose mRNA is 
up-regulated in the tumors were also produced in the tumor, 
we decided to focus on the two chemokines whose mRNA is 
most profoundly present in the tumors: CCL2 and CCL7. Using 
ELISA, we showed that high protein levels of both CCL2 and 
CCL7 were detected in the tumors relative to normal lung tis-
sue (Fig. 5E). Notably, the protein levels of CCL2 and CCL7 
in the tumor were much higher than in the blood of the tumor-
bearing mice (2577 ± 159 pg/mg of protein versus 189 ± 25 pg/
ml of blood for CCL2 and 1341 ± 67 pg/mg of protein versus 
96 ± 22 pg/ml of blood for CCL2), thus suggesting that these 
chemokines may attract CCR2-expressing monocyte subpop-
ulations to the tumor microenvironment.30–33 In addition, the 
unique pattern of chemokine expression in the tumor demon-
strates that the orthotopic tumor implantation approach avoids 
the induction of changes in gene expression in the entire lung 
microenvironment and restricts them to the confined area of 
the tumor.
Upon Implantation in the Lung, Human 
Lung Cancer Cells Generate a Single 
Pulmonary Nodule that, Over Time, 
Locally Grows and Forms Metastasis
In the final part of the article, we tested the generaliz-
ability of our findings by investigating whether orthotopic 
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FIGURE 3. A–C, Fibroblast accumulation around 3LL tumors stained 1 and 3 weeks after implantation of 500 GFP-expressing 
3LL cells. Green: anti-GFP staining, blue: Hoechst nuclear staining, purple: anti-S100A4. Magnification (×10), Bar = 100 μm.  
A, Representative 1-week tumor section; (B) representative 3-week tumor section showing both the margin and the core of the 
tumor; (C) representative 3-week lung section 3 mm distant from the primary tumor site with the same markers as in panels  
A and B. D, A magnified image of anti-GFP and anti-S100A4 staining, arrowheads point to S100A4-positive GFP-negative cells.
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delivery of small numbers of human lung cancer cells is 
applicable for generating human NSCLC tumors in immune-
compromised recipient mice (NSG mice). In previously pub-
lished works that have used orthotopic implantation of human 
NSCLC cells, researchers report the injection of very large 
number of cells (106–107) and portray the formation of a non-
anatomically bound parenchymal, pleural, and mediastinal 
disease. To avoid these drawbacks, we decided to limit our 
injection to no more than 1 × 104 human lung carcinoma cells 
and to test two different human NSCLC cell lines: (1) the large 
cell carcinoma cell line H460 and (2) the adenocarcinoma cell 
line A549. Six weeks after the injection of 1 × 104 H460 cells, 
we killed the mice and found that tumors formed in 83% (5 of 
6) of injected mice (Fig. 6A). Moreover, when sampling the 
contralateral lung and the liver of these tumor-bearing mice, 
we found that 66% (4 of 6) of mice developed lung metas-
tasis (Fig. 6B) and 33% (2 of 6) developed liver metastasis 
(Fig. 6C). Notably, injection of a smaller number of H460 
cells (7.5 × 103) resulted in a slightly lower rate of tumor for-
mation (4 of 6, 66.6%). Similarly, we observed that 6 weeks 
after injection of 5 × 103 A549 cells, 100% of the injected mice 
(5 of 5) developed lung tumors (Fig. 6D). In addition, 60% 
(3 of 5) of the A549 injected mice also developed distant lung 
metastasis (Fig. 6B) but none of the animals developed liver 
metastasis. Taken together, these observations demonstrate 
that orthotopic delivery of small numbers of human NSCLC 
is a suitable approach to induce solitary lung tumor implants 
and that this approach is also an attractive modeling system to 
mimic the metastatic spread of human lung cancer from the 
lung to secondary organs.
DISCUSSION
The recent and ongoing emergence of lung cancer 
screening programs is anticipated to significantly increase 
the number of patients diagnosed with early-stage lung 
cancer.34–36 This trend emphasizes the growing need for an 
FIGURE 4. A and B, Immune cell accumulation around 3LL tumors stained 3 weeks after implantation of 500 GFP-expressing 
3LL cells. Green: anti-GFP staining, blue: Hoechst nuclear staining, red: anti-CD45. Bar = 100 μm. A, Representative 3-week tumor 
section showing both the margin and the core of the tumor and (B) representative 3-week lung section 3 mm distant from the pri-
mary tumor site. C, Representative dot-plot analysis of the staining of lung- and tumor-derived immune cells (CD45-gated cells) for 
their forward and side scatter and for the cell surface markers CD11b and Gr-1 are shown. Two right panels: forwards/side scatter 
plots. Two left panels: CD11b/GR1 plots. The percentages of each population of cells out of total gated cells are shown.
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FIGURE 5. A–D, The fold increase or decrease in expression of mRNA for the chemokines CXCL-2, 3, 12, 16 and CCL-2, 3, 5, 7, 
17, 22 in 3LL cells in vitro (3LL cells) and in 3LL tumors in vivo (tumor) relative to normal lungs in vivo (lung) is shown. The data 
were acquired using quantitative polymerase chain reaction, and the fold increase or decrease in chemokine expression is always 
presented relative to normal lung tissue. The chemokines in the figure are divided into four distinct groups of chemokine accord-
ing to their relative mRNA expression in the native lung and in 3LL cells in culture. (This division is based on gene-chip data that 
we have analyzed and whose complete result is not shown here.) A, Chemokines whose mRNA expression is nearly absent both 
in cultured 3LL cells and in the lungs (CXCL2 and CXCL3); (B) chemokines whose mRNA is expressed by cultured 3LL cells but is 
absent in the lungs (CCL2 and CCL7); (C) chemokines whose mRNA is absent in cultured 3LL cells but is highly expressed in the 
lungs (CXCL12, CXCL16, CCL5, also defined as lung homeostatic chemokines); and (D) chemokines whose mRNA levels are low 
in cultured 3LL cells but show intermediate expression in the lungs (CCL3, CCL17, and CCL22). E, The CCL2 and CCL7 protein 
content (picograms of chemokine per milligrams of protein) in 3LL tumors and control normal lung parenchyma is shown.
56 Copyright © 2014 by the International Association for the Study of Lung Cancer
Weiss et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015
accurate early-stage lung cancer modeling system that will 
allow researchers to follow the dynamics of cancer growth 
and spread in and from the native lung microenvironment, and 
consequently, facilitate the future discovery of key molecular 
mechanisms that govern disease progression.4–6 In this article, 
we attempted to address this challenge and present a novel 
lung cancer model that is based on refined and accurate deliv-
ery of very small numbers of either human or murine lung 
cancer cells directly into the lung parenchyma. By implement-
ing this technique, we were able to closely mimic in vivo the 
clinical sequence of events that characterize the propagation 
of early-stage human NSCLC. More specifically, using either 
human or murine lung cancer cells, the experimental meth-
odology successfully induced a solitary microscopic pulmo-
nary nodule that was surrounded by normal lung parenchyma 
and that during a follow-up period of 1 to 6 weeks locally 
grew and spread. Remarkably, we found that the syngeneic 
lung carcinoma tumors were highly invasive and also induced 
the accumulation of fibroblasts and distinct populations of 
infiltrating leukocytes in the tumor leading edge. Therefore, 
we suggest that our new model can provide a useful tool to 
investigate various levels of tumor cell communications both 
with the lung stroma and with lung-infiltrating leukocytes and 
that the model may shed light on the outcomes of these com-
munications in regard of tumor growth and invasion. Finally, 
the ability of locally implanted human lung cancer cells to 
metastasize to secondary sites is analogous to the pathologic 
course of human NSCLC metastasis making our model useful 
for addressing the metastatic potential of human lung cancers 
and their in vivo susceptibility to anticancer drugs.
Notably, our findings contrast with previous attempts by 
several research groups, which as a result of the accelerated 
interest in recent years in the original tumor microenviron-
ment have also tried to model lung cancer by directly injecting 
malignant cells to the lung parenchyma.23,24,37–39 These initial 
attempts, made with both human and murine lung cancer cells, 
have reported important findings that have highlighted the 
significance of mimicking the disease in its native anatomic 
location.12,39 Nonetheless, the methodology reported in these 
studies suffers from several major limitations that prevent the 
accurate mimicry of early-stage lung cancer. Indeed, unlike 
this article, these studies reported the injection of large num-
bers of tumor cells in relatively large volumes of cell suspen-
sions (e.g., >1 × 106 cells in 20 μl volume).23,39 In addition, the 
researchers relied on large needles and syringes to inject their 
tumor cells.24,37–39 As a result, for example, their technique lead 
both to the early spread of cells from the lung to the thorax in 
a manner that does not relate to the pathologic behavior of 
early-stage human lung cancer and to metastasis of the tumor 
to axillary lymph nodes that are not considered a primary site 
for metastasis of early-stage lung cancer.23,39 The centrality 
of these limitations was further evident when we attempted 
to replicate these previously published methodologies in our 
own laboratory. Specifically, in our hands, we noticed that the 
use of large needles and large injection volumes was associ-
ated with excessive tissue damage and that the avoidance of 
FIGURE 6.  Representative histologic sections from the lungs and liver of an NSG mouse that was killed 6 weeks after injec-
tion of H460 and A549 cells into the left lung. A, H460 tumor in the left lung (magnification, ×4); (B) H460 micrometastasis in 
contralateral lung (magnification ×10); (C) H460 metastasis in the liver (magnification, ×10); (D) A549 tumor in the left lung 
(magnification, ×4); and (E) H460 distant micrometastasis (magnification, ×10).
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stereotactic guidance for injection made it difficult to assure 
the precise location and depth of tumor cell injection.
The methodology suggested in this article overcomes 
these critical technical considerations by utilizing smaller 
syringes, by dramatically reducing both the number of injected 
cells and the volume of cell suspension (i.e., 500 cells in 2 μl 
volume), and by introducing the cells under the guidance of a 
stereotactic injection system. As a result, we were also able to 
ensure the precise depth and location of injection and to estab-
lish a refined method of tumor cell implantation that avoids 
the early spread of tumor cells to the chest wall and to extra 
thoracic lymph nodes such as axillary nodes that are not often 
involved in early stages of NSCLC.3 Indeed, to further solidify 
the anatomically confined nature of our injection methodology, 
evidence from GFP-tagged cells demonstrated that only a sin-
gle tumor focus was formed after tumor cell injection and that 
no singular cancer cells were found distant to the original injec-
tion site. In addition, and unlike previous works, the histologic 
appearance of the lung tissue as early as 1 week after tumor 
cell implantation showed that the lung parenchyma surround-
ing the tumor was intact. Thus, we conclude that the technical 
modifications that we introduced allowed for the development 
of orthotopically induced tumors that recapitulate many impor-
tant characteristics of early-stage human lung cancer.
By being able to better model malignant diseases in a 
manner that closely resembles clinical disease characteristics, 
both with regard to primary anatomic location and with regard 
to secondary sites of spread and metastasis, we propose that 
our orthotopic lung cancer modeling system has the poten-
tial to characterize distinct cellular and immunologic events 
that occur specifically in the tumor’s microenvironment and 
that may represent the signature of pathologic processes that 
support the tumor’s growth and spread.7,9 Some intriguing 
evidence for this has been demonstrated in the latter part of 
the article, where we found, for example, that orthotopically 
implanted 3LL tumors induced the time-dependent accumula-
tion of both fibroblast and leukocytes in the tumors expanding 
margin and that upon deeper probing of the tumor-associated 
leukocytes, a population of CD45+ Gr-1med CD11bhigh cells 
that may exhibit immune suppressive properties was detected 
specifically in the tumors relative to their surrounding normal 
lung parenchyma.29,40 We further observed a specific profile 
of chemokines that were expressed by the tumor such that the 
myeloid cell attracting chemokines (CXCL2 and CXCL3) 
and the CCR2-binding chemokines (CCL2 and CCL7) were 
specifically up-regulated in the tumors relative to their sur-
rounding normal lung parenchyma, whereas the homeostatic 
lung chemokines (CXCL12, CXCL16, and CCL5) were spe-
cifically down-regulated in the tumors.30–33 Together, these 
findings sketch two potentially interesting tumor–stroma 
crosstalk pathways that may be involved in regulating lung 
cancer tumor growth and spread. First, the expression of the 
myeloid cell attracting chemokines (CXCL2 and CXCL3) 
in the tumors and the specific recruitment of CD45+ Gr-1med 
CD11bhigh cells to the tumors may represent an immune modu-
lation mechanism that favors tumor growth.29,40 Second, the 
expression of CCL7 and CCL2 in the tumors and the specific 
accumulation of fibroblasts at the tumor margin may represent 
a molecular and cellular signature to the invasive nature of 
the tumor.41,42 Although these two pro-tumorogenic pathways 
which have been detected by our model require further valida-
tion, some initial evidence for the first proposition comes from 
previous publications which have reported that the knocking 
down of CXCL2 in metastatic breast cancer cells reduced the 
accumulation of myeloid suppressive cells in the tumor.43,44 
These studies have further demonstrated that the CXCR2/
CXCL2/CXCL3 axis is tumorogenic.43,44 Some support for 
the second proposition comes from research which has shown 
that cancer-associated fibroblast-derived CCL7 specifically 
promoted the invasion and migration of malignant cells. These 
researchers further showed that neutralizing the tumor recep-
tors for CCL7 (CCR1, CCR2, and CCR3) may inhibit tumor 
cell migration.41,42
Importantly, we must acknowledge the inherent limi-
tations of the immune-compromised model used by us for 
implanting human lung cancer cells rather than murine lung 
cancer cells in mice. In addition, we acknowledge that tumor 
growth may vary considerably between distinct types and pro-
tocols of implanted cells and mice hosts (e.g., immune sta-
tus, strain, age, microbiota). And yet, the advantages of our 
orthotopic lung cancer models, which are based on delivery of 
small number of tumor cells directly into the lung parenchyma, 
are clear as these models more accurately mimic the clinical 
manifestation of early-stage human NSCLC. As such, we sug-
gest that our model system represents an attractive platform to 
dissect key molecular mechanisms that govern not only lung 
tumor propagation and metastasis but also tumor resistance to 
drugs. We therefore anticipate that this and similar orthotopic 
models adapted for other types of tumors and organs will be 
highly attractive for studies on the efficacy of anticancer drugs 
under various clinically relevant settings.
STATEMENT OF TRANSLATIONAL RELEVANCE
The recent and ongoing emergence of lung cancer 
screening programs is anticipated to significantly increase the 
number of patients diagnosed with early-stage lung cancer. 
This trend emphasizes the growing need for an accurate early-
stage lung cancer modeling system that will allow research-
ers to follow the dynamics of cancer growth and spread in 
and from the native lung microenvironment, and consequently, 
facilitate the future discovery of key molecular mechanisms 
that govern disease progression. In this article, we present 
a novel stereotactic-guided injection-based orthotopic lung 
cancer model that closely mimics the pathologic sequence of 
events that characterizes early-stage human lung cancer prop-
agation. This model thus serves as an attractive platform to 
probe tumor–stromal cell interactions and to test therapeutic 
targets under conditions that reflect early-stage lung cancer.
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